DOCSLIB.ORG

Interleukin Signalling

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interleukin Signalling View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Magazine R760 Primer superfamily is the utilization of following type I and II cytokine shared cytokine receptor subunits receptor oligomerization, including – a single receptor chain may the MAPK (mitogen-activated participate in the generation of the protein kinase, also known as ERK Interleukin functional receptor complex for for extracellular-signal-regulated signalling multiple different ligands. As such, kinase) cascade, the JAK/STAT the superfamily can be subdivided pathway (Janus kinase/signal into receptors sharing the common transducer and activator of Christian A. J. Voβhenrich and β chain, the common γ chain, the transcription), and the PI3-K James P. Di Santo gp130 molecule, the IL-20Rβ chain (phosphoinositide 3-kinase) and the IL-22Rα chain (see Table cascade. The JAK/STAT pathway Interleukins are low molecular 1). In addition, a number of appears uniquely coupled to type I weight proteins produced by receptor chains are shared by two and II cytokine receptor signaling, leukocytes that bind to cell different ligand-binding receptor and has been the subject of surface receptors and act in an complexes: the IL-4Rα, the IL-7Rα, considerable analysis: the current autocrine and/or paracrine the IL-12Rβ1, the IL-10Rβ and the model is depicted in Figure 1. fashion. These secreted factors IL-20Rα chain. Homodimerization, hetero- modify the cell differentiation Receptor subunit oligo- dimerization or heterotrimerization program (survival, proliferation, merization plays an essential role of receptor chains in the presence maturation, induction of or in signaling via the type I and II of ligand (Table 1) generates a protection from apoptosis) of the cytokine receptors. The activation signaling-proficient complex, target cells to which they bind. As of multiple, distinct intracellular which brings together the such, interleukins impact on cascades has been documented receptor-bound JAKs. JAK diverse biological processes: tissue growth and repair, Table 1. The type I and II cytokine receptors. hematopoietic homeostasis, and Type Ligands Receptor JAK STAT Inhibitora at multiple levels of the host γ γ defense against pathogens. It is I c-dependent: c + ligand-specific 1,3 5,3 CIS (IL-2), IL-2, 7, 9, receptor chain, except SOCS1 (IL-2), therefore not surprising that the 15, 21 IL-2R and IL-15R which SOCS3 (IL-2,9) rather generic designation use IL-2Rβ plus a ‘interleukin’ does not refer to a specific α-chainb γ homogeneous family of proteins, IL-4 Type I IL-4R, c + 1,3 6 SOCS1,3 but instead to groups of proteins IL-4Rα ; type II IL-4R, IL-4Rα + IL-13Rα that adopt different three- β β c-dependent: c + ligand-specific 2 5 CIS (IL-3), dimensional structures, bind to IL-3, 5, GM-CSF receptor chain, SOCS1 (IL-3), distinct classes of receptors, and only βc binds JAK SOCS3 (IL-3) initiate unique signal transduction gp130-dependent: 1,2,Tyk2 3 SOCS1,2 (IL-6,LIF), pathways. Our discussion of IL-6, 11, OSM, SOCS3 (IL-6,11,LIF) interleukins will be structured CNTF, LIF, CT-1 β β according to the two main classes IL-12 (p35/p40) IL-12R 1, IL-12R 2 2,Tyk2 4 IL-23 (p19/p40) IL-12Rβ1?4 of receptors to which they bind: IL-27 (p28/EBI3) WSX-1 the type I and type II cytokine TSLP TSLPR, IL-7Rα – 5 SOCS1 receptor families and the IL- GH GHR homodimer 2 5 CIS, SOCS1,2,3 1R/TLR (interleukin-1 receptor/ EPO EPOR homodimer 2 5 CIS, SOCS3 Toll-like receptor) superfamily. TPO TPOR homodimer 2 5 SOCS1,3 Prolactin PRLR homodimer 2 5 CIS, SOCS1,3 Leptin Leptin receptor 2 3 SOCS3 Type I and II cytokine receptor homodimer families G-CSF G-CSFR homodimer 2 3 (1,5) Type I cytokine receptors are II IFNα/β IFNα/βRα, β 1,Tyk2 1,2 SOCS1 transmembrane proteins with four IFNγ IFNγRα, β 1,2 1 SOCS1,3 conserved cysteine residues and a IL-10 IL-10Rα, IL-10Rβ 1,Tyk2 3 ND α β Trp-Ser-X-Trp-Ser (WSXWS) motif IL-22 (IL-TIF) IL-22R , IL-10R ? 1,3,5 ND IL-20 IL-22Rα, IL-20Rβ ?3ND in their extracellular domain, and a IL-20Rα, IL-20Rβ cytoplasmic tail containing IL-24 (MDA-7) IL-22Rα, IL-20Rβ consensus motifs (‘boxes’ 1 and 2) IL-20Rα, IL-20Rβ ?3ND involved in signal transduction. IL-19 IL-20Rα, IL-20Rβ ?3ND The type II cytokine receptors are The list includes the functional receptors for a given cytokine as well as the JAK/STAT mol- related but lack the extracellular ecules activated via the receptor. aPhosphatases and PIAS not taken into account. bIL-2Rα WSXWS motif (Table 1). Ligands and IL-15Rα are not type I cytokine receptor chains. for these receptors belong to a GM-CSF, granulocyte/monocyte-colony-stimulating factor; TSLP, thymic stroma-derived lym- family characterized by the phopoietin; OSM, oncostatin M; CNTF, ciliary neurotrophic factor; LIF, leukemia inhibitory factor; CT, cardiotrophin; GH, growth hormone; EPO, erythropoietin; TPO, thrombopoietin; presence of four α helices. One γ β IFN, interferon; c, common cytokine receptor gamma chain; c, common cytokine receptor predominant characteristic of the beta chain; IL-TIF, interleukin-10-related T-cell-derived inducible factor; MDA, melanoma dif- type I and II cytokine receptor ferentiation-associated antigen; ND, not described. Magazine R761 A Ligand B Ras JAK JAK SOCS S P CIS T P S A T PIAS Raf T A T Shc P JAK JAK Sos T S P P T P Grb2 A T A P T Gab2 S P p85 P S T S T P Shc T A A P P T A T S T PI3K S T A MAPK Nucleus T cascade PKB Current Biology Figure 1. Signal transduction via type I and type II cytokine and STAT proteins. (B) Pathways of Shc-mediated PKB and receptors. (A) Ligand-induced oligomerisation of receptor sub- MAPK activation and STAT-induced SOCS/CIS/PIAS inhibition. units leads to receptor phosphorylation thereby recruiting Shc See text for details. autophosphorylation, as well as (Figure 1). The adaptor molecule multiple Grb2 proteins thereby receptor tyrosine phosphorylation Grb2 plays a major role in initiating organizing and potentiating the (Figure 1) generates specific the MAPK cascade. Upon receptor signals by the activated receptor; docking sites for adaptor proteins binding, Grb2 recruits, via its in this way, adaptors serve as a containing Src homology 2 (SH2) amino-terminal SH3 domain, the core for building multiple signaling domains or phosphotyrosine- guanine nucleotide exchange pathways in parallel. binding (PTB) domains for factor Sos to the plasma The regulation of signaling building an intracellular signaling membrane where it activates the through type I and II cytokine scaffold. STAT proteins bind to GTPase Ras, which in turn receptors occurs at multiple levels: the receptor via SH2 domains, activates MAPK/ERK, via several soluble forms of ligand-binding and themselves become tyrosine intermediate kinases. Activation of receptor subunits may act to phosphorylated. The the MAPK/ERK pathway is not sequester extracellular ligands phosphorylated STAT proteins specific to the type I and II under some conditions; then dissociate from the receptor, cytokine receptors and the competition for shared receptor homodimerize or heterodimerize substrates of the activated MAPKs subunits can decrease the (again via their SH2 domains), and are diverse, including transcription efficiency of signaling; and tyrosine translocate into the nucleus where factors and other kinases. phosphatases (including SHP-1, they stimulate target gene The MAPK cascade is just one SHP-2, and CD45) may act to transcription (Figure 1). of several pathways involved in dampen formation or stability of Four JAKs (JAK1, JAK2, JAK3 signaling from Grb2. While the intracellular signaling complexes. and Tyk2) and six STAT proteins amino-terminal SH3 domain of Suppressor of cytokine signaling (STAT1–6) have been identified in Grb2 binds to Sos, its carboxy- (SOCS) proteins are a family of mammalian cells. Curiously, no terminal SH3 domain recruits, molecules that can bind activated simple rules apply to the probably at the same time, the JAKs or phosphorylated receptor utilization of the different JAKs Gab1 or Gab2 adaptor proteins. chains and thereby impede and STATs with different These proteins are phosphoryl- docking of STATs and/or adaptor receptors. Involvement of different ated and serve as docking sites molecules. Different SOCS JAK and STAT proteins in signal for other proteins, such as the p85 proteins are induced by different transduction pathways from type I subunit of PI3-K, the cytokines. The SOCS family and II cytokine receptors may be phosphorylation of which leads to includes eight members: cytokine- highly specific or promiscuous the activation of the protein inducible SH2-domain-containing (Table 1). kinase B (PKB) pathway (Figure 1). protein (CIS) and SOCS1–7, which As mentioned above, the Some cytokine receptors, for all contain a protein motif JAK/STAT pathway is an example IL-7Rα, have direct designated the SOCS box, also important, but by no means the binding sites for the SH2 domain found in a number of proteins only, signal transduction pathway of the p85 subunit of PI3-K, unrelated to cytokine signaling. triggered by type I and II cytokine thereby allowing direct stimulation A different family of inhibitors — receptors. Recruitment of SH2- or of this specific pathway. protein inhibitors of activated STAT PTB-domain adaptors to the Scaffolding proteins like Shc also (PIAS) — has been recently phosphorylated receptor chains bind to phosphorylated receptor described to bind activated STAT can result in the activation of the chains and become proteins and prevent their MAPK and the PI3-K pathways phosphorylated.
Load more

Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Mechanism of Homodimeric Cytokine Receptor Activation and Dysregulation by Oncogenic Mutations
    This is a repository copy of Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/155270/ Version: Accepted Version Article: Wilmes, Stephan, Hafer, Maximillian, Vuorio, Joni et al. (15 more authors) (2020) Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science. pp. 643-652. ISSN 0036-8075 https://doi.org/10.1126/science.aaw3242 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Submitted Manuscript: Confidential Title: Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations Authors: 5 Stephan Wilmes1, 2*, Maximillian Hafer1*, Joni Vuorio3,4, Julie A. Tucker5, Hauke Winkelmann1, Sara Löchte1, Tess A. Stanly5, Katiuska D. Pulgar Prieto5, Chetan Poojari3, Vivek Sharma3,6, Christian P. Richter1, Rainer Kurre1, Stevan R. Hubbard7, K. Christopher Garcia8,9, Ignacio Moraga2, Ilpo Vattulainen3,4,10†, Ian S. Hitchcock5† and Jacob Piehler1† Affiliations: 10 1 Department of Biology and Center of Cellular Nanoanalytics, University of Osnabrück, 49076 Osnabrück, Germany.
    [Show full text]
  • Stony Brook University
    SSStttooonnnyyy BBBrrrooooookkk UUUnnniiivvveeerrrsssiiitttyyy The official electronic file of this thesis or dissertation is maintained by the University Libraries on behalf of The Graduate School at Stony Brook University. ©©© AAAllllll RRRiiiggghhhtttsss RRReeessseeerrrvvveeeddd bbbyyy AAAuuuttthhhooorrr... Regulation of Dimerization and Activation of the Thrombopoietin Receptor A Dissertation Presented by Miki Itaya to The Graduate School in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Biochemistry and Structural Biology Stony Brook University December 2012 Copyright by Miki Itaya 2012 Stony Brook University The Graduate School Miki Itaya We, the dissertation committee for the above candidate for the Doctor of Philosophy degree, hereby recommend acceptance of this dissertation. Steven O. Smith, Ph.D. - Dissertation Advisor Professor, Department of Biochemistry and Cell Biology Erwin London, Ph.D. - Chairperson of Defense Professor, Department of Biochemistry and Cell Biology Robert C. Rizzo, Ph.D. Associate Professor, Department of Applied Mathematics and Statistics Nancy Reich Marshall, Ph.D. Professor, Department of Molecular Genetics and Microbiology This dissertation is accepted by the Graduate School Charles Taber Interim Dean of the Graduate School ii Abstract of the Dissertation Regulation of Dimerization and Activation of the Thrombopoietin Receptor by Miki Itaya Doctor of Philosophy in Biochemistry and Structural Biology Stony Brook University 2012 The thrombopoietin receptor (TpoR) is
    [Show full text]
  • Amphioxus TLR Signaling Adaptors Act As Negative Regulators In
    Novel Toll/IL-1 Receptor Homologous Region Adaptors Act as Negative Regulators in Amphioxus TLR Signaling This information is current as Jian Peng, Xin Tao, Rui Li, Jingru Hu, Jie Ruan, Ruihua of September 29, 2021. Wang, Manyi Yang, Rirong Yang, Xiangru Dong, Shangwu Chen, Anlong Xu and Shaochun Yuan J Immunol published online 31 August 2015 http://www.jimmunol.org/content/early/2015/08/30/jimmun ol.1403003 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2015/08/30/jimmunol.140300 Material 3.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published August 31, 2015, doi:10.4049/jimmunol.1403003 The Journal of Immunology Novel Toll/IL-1 Receptor Homologous Region Adaptors Act as Negative Regulators in Amphioxus TLR Signaling Jian Peng,*,1 Xin Tao,* Rui Li,* Jingru Hu,* Jie Ruan,* Ruihua Wang,* Manyi Yang,* Rirong Yang,* Xiangru Dong,* Shangwu Chen,* Anlong Xu,*,† and Shaochun Yuan* Studies have shown that the basal chordate amphioxus possesses an extraordinarily complex TLR system, including 39 TLRs and at least 40 Toll/IL-1R homologous region (TIR) adaptors.
    [Show full text]
  • Immuno-Endocrine Interactions in Intestinal Inflammation
    IMMUNO-ENDOCRINE INTERACTIONS IN INTESTINAL INFLAMMATION PhD Thesis- Shajib, MS; McMaster University-Medical Sciences Immuno-endocrine interactions in intestinal inflammation By Md. Sharif Shajib, BSc. (Hons) A Thesis Submitted to the School of Graduate Studies in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy McMaster University © Copyright by Md. Sharif Shajib, 2017. PhD Thesis- Shajib, MS; McMaster University-Medical Sciences Descriptive notes Doctor of Philosophy (2017) McMaster University, Hamilton, Ontario (Medical Sciences) TITLE Immuno-endocrine interactions in intestinal inflammation AUTHOR Md. Sharif Shajib, BSc. (Hons) SUPERVISOR Dr. Waliul I. Khan NUMBER OF PAGES: XX, 292. II PhD Thesis- Shajib, MS; McMaster University-Medical Sciences Lay abstract The gut produces most of the serotonin found in our body, where it regulates many normal functions. A group of special cells, named enterochromaffin cells, produces nearly all of the serotonin in the gut. In diseases of the gut, especially ones that involve inflammation resulting in symptoms like abdominal pain, diarrhea and bleeding, the number of these cells and serotonin concentration are different from that in the normal gut. I found that these changes are controlled by a particular protein produced by immune cells, called interleukin-13, and alteration in serotonin levels, in turn, contributes to the inflammatory process. Our laboratory experiments with cells and animals establish this connection between interleukin-13 and serotonin in gut inflammation. We further confirm this association between interleukin-13 and serotonin in human inflammatory bowel disease. Moreover, we identify a potential genetic cause of these changes in serotonin concentrations which may ultimately result in inflammatory bowel disease.
    [Show full text]
  • GM-CSF Receptor-Beta, Human, Recombinant Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor Receptor Beta
    GM-CSF Receptor-beta, human, recombinant Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor Receptor beta Instruction Manual Catalog Number C-60430 Synonyms CSF2RB,Colony Stimulating Factor 2 Receptor, Beta, Low-Affinity (Granulocyte-Macrophage), GM-CSF/IL-3/IL-5 Receptor Common Beta Subunit, CDw131, IL3RB, SMDP5, IL5RB, Interleukin 3 Receptor/Granulocyte-Macrophage Colony Stimulating Factor 3 Receptor, Beta (High Affinity), Colony-Stimulating Factor-2 Receptor, Beta, Low-Affinity, GM-CSF/IL-3/IL-5 Receptor Common Beta-Chain, Cytokine Receptor Common Subunit Beta, CD131 Antigen, CD131 Description GM-CSF Receptor-beta, also known as CSF2RB is a member of the type I cytokine receptor family. CSF2RB is a high affinity receptor for interleukin-3, interleukin-5 as well as granulocyte- macrophage colony-stimulating factor. The CSF2RB unique form of receptor assembly applies also to IL-3 and IL-5 receptors, providing a structural basis for understanding their activation mechanism which is essential for the development of therapeutics. Human recombinant GM-CSF Receptor-beta produced in Sf9 cells is a single, glycosylated polypeptide chain of 435 amino acids (17-443 a.a), having a molecular mass of 49.7 kDa (migrates at 40-57 kDa on SDS-PAGE under reducing conditions). CSF2RB is fused to an 8 amino acid His-tag at the C-terminus and purified using proprietary chromatographic techniques. Quantity 10 µg Molecular Mass 49.7 kDa Source Sf9 insect cells Biological-Activity NA Specific Activity NA Formulation Sterile-filtered, clear protein solution (0.5 mg/ml) containing phosphate-buffered saline (pH 7.4) and 10% glycerol. Reconstitution Please Note: Always centrifuge product briefly before opening vial.
    [Show full text]
  • Facteurs Génétiques De Prédisposition a La Maladie Coeliaque Et L’Oesophagite Éosinophilique
    Université de Montréal FACTEURS GÉNÉTIQUES DE PRÉDISPOSITION A LA MALADIE COELIAQUE ET L’OESOPHAGITE ÉOSINOPHILIQUE Par Freha Nour el Hayet CHERIEF Département de Microbiologie et Immunologie Faculté de Médecine Mémoire présenté à la Faculté des études supérieures en vue de l’obtention du grade de Maîtrise en Microbiologie et Immunologie Novembre 2012 © Freha Nour el Hayet CHERIEF, 2012 i Université de Montréal Faculté des études supérieures Ce mémoire intitulé : FACTEURS GÉNÉTIQUES DE PRÉDISPOSITION A LA MALADIE COELIAQUE ET L’OESOPHAGITE ÉOSINOPHILIQUE Présenté par : Freha nour el hayet CHERIEF a été évalué par un jury composé des personnes suivantes : Ali Ahmad Président-rapporteur Idriss Djilali-Saïah Directeur de recherche Cristophe Faure Membre du jury ii Résumé Les maladies immunitaires chroniques incluant les maladies auto-immunes et inflammatoires touchent 20 à 25% de la population des pays occidentaux. La comparaison des taux de concordance chez les jumeaux ou l’histoire familiale de sujets atteints de la maladie cœliaque (maladie auto-immune de l’intestin) ou de l’œsophagite éosinophilique (maladie inflammatoire de l’œsophage) indiquent que des facteurs génétiques et environnementaux interviennent dans la susceptibilité à ces maladies. Cependant, ces études ne distinguent pas de manière claire la prédisposition génétique selon l’hétérogénéité clinique (enfants versus adultes) ou ethnique (stratification des populations). Méthodes. Les haplotypes HLA de prédisposition à la maladie cœliaque et les polymorphismes des gènes candidats
    [Show full text]
  • WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT (51) International Patent Classification: achusetts 021 15 (US). THE BROAD INSTITUTE, A61K 51/10 (2006.01) G01N 33/574 (2006.01) INC. [US/US]; 415 Main Street, Cambridge, Massachu C07K 14/705 (2006.01) A61K 47/68 (2017.01) setts 02142 (US). MASSACHUSETTS INSTITUTE OF G01N 33/53 (2006.01) TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). (21) International Application Number: PCT/US2017/055625 (72) Inventors; and (71) Applicants: KUCHROO, Vijay K. [IN/US]; 30 Fairhaven (22) International Filing Date: Road, Newton, Massachusetts 02149 (US). ANDERSON, 06 October 2017 (06.10.2017) Ana Carrizosa [US/US]; 110 Cypress Street, Brookline, (25) Filing Language: English Massachusetts 02445 (US). MADI, Asaf [US/US]; c/o The Brigham and Women's Hospital, Inc., 75 Francis (26) Publication Language: English Street, Boston, Massachusetts 021 15 (US). CHIHARA, (30) Priority Data: Norio [US/US]; c/o The Brigham and Women's Hospital, 62/405,835 07 October 2016 (07.10.2016) US Inc., 75 Francis Street, Boston, Massachusetts 021 15 (US). REGEV, Aviv [US/US]; 15a Ellsworth Ave, Cambridge, (71) Applicants: THE BRIGHAM AND WOMEN'S HOSPI¬ Massachusetts 02139 (US). SINGER, Meromit [US/US]; TAL, INC. [US/US]; 75 Francis Street, Boston, Mass c/o The Broad Institute, Inc., 415 Main Street, Cambridge, (54) Title: MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS CD4 FIG.
    [Show full text]
  • A Closer Look at JAK/STAT Signaling Pathway Emira Bousoik Chapman University
    Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 7-31-2018 “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway Emira Bousoik Chapman University Hamidreza Montazeri Aliabadi Chapman University, [email protected] Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles Part of the Amino Acids, Peptides, and Proteins Commons, Cancer Biology Commons, Cell Anatomy Commons, Cell Biology Commons, Enzymes and Coenzymes Commons, Oncology Commons, and the Other Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Bousoik E, Montazeri Aliabadi H. “Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Front. Oncol. 2018;8:287. doi: 10.3389/fonc.2018.00287 This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact [email protected]. “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway Comments This article was originally published in Frontiers in Oncology, volume 8, in 2018. DOI: 10.3389/ fonc.2018.00287 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. Copyright The uthora s This article is available at Chapman University Digital Commons: https://digitalcommons.chapman.edu/pharmacy_articles/590
    [Show full text]
  • A Truncated TIR-NBS Protein TN10 Pairs with Two Clustered TIR-NBS-LRR Immune Receptors and Contributes to Plant Immunity in Arabidopsis
    International Journal of Molecular Sciences Article A Truncated TIR-NBS Protein TN10 Pairs with Two Clustered TIR-NBS-LRR Immune Receptors and Contributes to Plant Immunity in Arabidopsis Yongming Chen 1, Guitao Zhong 1,2, Huiren Cai 1,2, Renjie Chen 1, Na Liu 1, Wei Wang 1,* and Dingzhong Tang 1,* 1 State Key Laboratory of Ecological Control of Fujian-Taiwan Crop Pests, Key Laboratory of Ministry of Education for Genetics, Breeding and Multiple Utilization of Crops, Plant Immunity Center, Fujian Agriculture and Forestry University, Fuzhou 350002, China; [email protected] (Y.C.); [email protected] (G.Z.); [email protected] (H.C.); [email protected] (R.C.); [email protected] (N.L.) 2 College of Life Science, Fujian Agriculture and Forestry University, Fuzhou 350002, China * Correspondence: [email protected] (W.W.); [email protected] (D.T.) Abstract: The encoding genes of plant intracellular nucleotide-binding site (NBS) and leucine-rich repeat (LRR) domain receptors (NLRs) often exist in the form of a gene cluster. Several recent studies demonstrated that the truncated Toll/interleukin-1 receptor-NBS (TIR-NBS) proteins play important roles in immunity. In this study, we identified a large TN gene cluster on Arabidopsis ecotype Col-0 chromosome 1, which included nine TN genes, TN4 to TN12. Interestingly, this cluster also contained two typical TIR-NBS-LRR genes: At1g72840 and At1g72860 (hereinafter referred to as TNL40 and Citation: Chen, Y.; Zhong, G.; TNL60, respectively), which formed head-to-head genomic arrangement with TN4 to TN12. However, Cai, H.; Chen, R.; Liu, N.; Wang, W.; the functions of these TN and TNL genes in this cluster are still unknown.
    [Show full text]
  • Transformation of Hematopoietic Cells and Activation of JAK2-V617F by IL-27R, a Component of a Heterodimeric Type I Cytokine Receptor
    Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor Anuradha Pradhan, Que T. Lambert, and Gary W. Reuther* Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 Edited by Stephen P. Goff, Columbia University College of Physicians and Surgeons, New York, NY, and approved October 5, 2007 (received for review March 14, 2007) From a patient with acute myeloid leukemia (AML), we have shown to be leukemogenic in mice (9), further validating our identified IL-27Ra (also known as TCCR and WSX1) as a gene whose approach to identify genes that contribute to leukemia formation. expression can induce the transformation of hematopoietic cells. In this study, we have used a functional genetic screen to IL-27Ra (IL-27R) is a type I cytokine receptor that functions as the identify genes that contribute to myeloid cell transformation and ligand binding component of the receptor for IL-27 and functions perhaps AML formation. Here, we describe our identification of with the glycoprotein 130 (gp130) coreceptor to induce signal the ligand binding component of the receptor for IL-27 (IL- transduction in response to IL-27. We show that IL-27R is expressed 27R), as a unique transforming gene product. We show that on the cell surface of the leukemic cells of AML patients. 32D IL-27R is expressed on the cell surface of leukemic cells of AML myeloid cells transformed by IL-27R contain elevated levels of patients and demonstrate that IL-27R can transform hemato- activated forms of various signaling proteins, including JAK1, JAK2, poietic cells in a JAK-dependent manner.
    [Show full text]
  • Regulation of Cytokine Gene Expression in Immunity and Diseases Advances in Experimental Medicine and Biology
    Advances in Experimental Medicine and Biology 941 Xiaojing Ma Editor Regulation of Cytokine Gene Expression in Immunity and Diseases Advances in Experimental Medicine and Biology Volume 941 Editorial Board IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel N.S. ABEL LAJTHA, Kline Institute for Psychiatric Research, Orangeburg, NY, USA JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA RODOLFO PAOLETTI, University of Milan, Milan, Italy More information about this series at http://www.springer.com/series/5584 Xiaojing Ma Editor Regulation of Cytokine Gene Expression in Immunity and Diseases Editor Xiaojing Ma State Key Laboratory of Microbial Metabolism, Sheng Yushou Center of Cell Biology and Immunology, School of Life Science and Biotechnology Shanghai Jiaotong University, Shanghai , China Department of Microbiology and Immunology Weill Cornell Medical College NY , USA ISSN 0065-2598 ISSN 2214-8019 (electronic) Advances in Experimental Medicine and Biology ISBN 978-94-024-0919-2 ISBN 978-94-024-0921-5 (eBook) DOI 10.1007/978-94-024-0921-5 Library of Congress Control Number: 2016955715 © Springer Science+Business Media Dordrecht 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.
    [Show full text]